Copper Cu 64 Dotatate and Octreotide: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Octreotide
Copper Cu 64 Dotatate
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Decreased copper Cu 64 dotatate efficacy
Interaction Deep Dive
Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2) which may affect imaging. Image patients with copper Cu 64 dotatate just prior to dosing with somatostatin analogs. For patients treated with long-acting somatostatin analogs, discontinue use 28 days prior to imaging with copper Cu 64 dotatate. For patients treated with short-acting somatostatin analogs, discontinue use 2 days prior to imaging with copper Cu 64 dotatate1.
Why it happens (mechanism)
Interference with the binding of copper Cu 64 dotatate to somatostatin receptors
Common questions
Can I take Copper Cu 64 Dotatate and Octreotide together?
Decreased copper Cu 64 dotatate efficacy Always confirm with your pharmacist or prescriber before making any change.
How serious is the Copper Cu 64 Dotatate and Octreotide interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Copper Cu 64 Dotatate or Octreotide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: Detectnet(TM) intravenous injection, copper Cu 64 dotatate intravenous injection. Curium US LLC (per manufacturer), Maryland Heights, MO, 2020. DailyMed
Keep reading about Octreotide
Keep reading about Copper Cu 64 Dotatate
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist